Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Jan 12, 2021 10:55am
163 Views
Post# 32275615

The floor is $2.71US+ brokers cut

The floor is $2.71US+ brokers cut Giving the size of the offering I doubt these brokers manage to sell all of the equities to one stakeholder hopefully I am wrong as many mentioned a single large holder would bring credibility along with analysts working with them.
Apart from some costs involved to close a deal like this these brokers need to sell the equities with a premium which bring me to the fact it is in their interest for the SP in the next few days. Weeks incorporate that premium.
Point is they ultimately want the SP rise from the bought deal price the higher it gets the more profit for the brokers.
After that the trick is the company keep the new investors convinced to hold on to their position as there is no immediate or medium term need for additional funding and they have two potential very lucrative programs which have promising prospects in 2021 and beyond add to that two commercialized drugs with growing sales.

<< Previous
Bullboard Posts
Next >>